USMLE Step 1 practice question: MEN 2A: RET proto-oncogene (medullary thyroid carcinoma, pheochromocytoma, hyperparathyroidism)

USMLE Step 1EndocrineGenetics

A 34-year-old woman comes to the physician because of a 4-month history of episodic pounding headaches, palpitations, and drenching sweats that last 10 to 20 minutes. Her father died of thyroid cancer at the age of 45 years, and her paternal aunt underwent neck surgery for “high calcium.” Her blood pressure is 168/102 mm Hg during an episode in the office and 138/88 mm Hg 1 hour later. She is 165 cm (5 ft 5 in) tall with normal body proportions. Examination shows a firm, 2-cm nodule in the right lobe of the thyroid gland. The lips and tongue appear normal. Laboratory studies show: Calcium: 11.1 mg/dL Parathyroid hormone: 94 pg/mL (N 10–65) Calcitonin: markedly increased Plasma free metanephrines: 6 times the upper limit of normal Fine-needle aspiration of the thyroid nodule shows nests of spindle-shaped and polygonal cells in an amorphous stroma that stains with Congo red.

Which of the following is the most likely genetic basis of this patient's condition?

  1. Inactivating mutation of a tumor suppressor gene encoding menin
  2. Inactivating mutation of the von Hippel-Lindau tumor suppressor gene
  3. Activating mutation of a gene encoding a receptor tyrosine kinase
  4. Inactivating mutation of a gene encoding a Ras GTPase-activating protein
  5. Activating mutation of the gene encoding the Gsα protein subunit
Show answer and explanation

Correct answer: C. Activating mutation of a gene encoding a receptor tyrosine kinase

This patient has medullary thyroid carcinoma (a thyroid nodule, markedly elevated calcitonin, and calcitonin-derived amyloid stroma on aspiration), pheochromocytoma (paroxysmal headaches, palpitations, sweating, hypertension, and elevated plasma metanephrines), and primary hyperparathyroidism (hypercalcemia with elevated PTH), with a family history suggesting autosomal dominant inheritance. This triad defines multiple endocrine neoplasia type 2A (MEN 2A).

MEN 2A and MEN 2B are caused by germline gain-of-function mutations in the RET proto-oncogene (chromosome 10q11.2), which encodes a transmembrane receptor tyrosine kinase for glial cell line–derived neurotrophic factor (GDNF) family ligands. Activating mutations cause ligand-independent dimerization or kinase activation and constitutive downstream signaling (e.g., RAS/MAPK and PI3K/AKT pathways), driving hyperplasia and then neoplasia of neural crest–derived parafollicular C cells and adrenal chromaffin cells. Because one mutant allele is sufficient, inheritance is autosomal dominant with high penetrance for medullary thyroid carcinoma. Loss-of-function RET mutations cause Hirschsprung disease (failed migration of enteric neural crest cells), which occasionally coexists with MEN 2A.

Clinical implications: first-degree relatives should undergo RET genetic testing, and carriers are offered prophylactic thyroidectomy at an age determined by the risk level of the specific mutation. In a patient with medullary thyroid carcinoma, pheochromocytoma must be excluded and, if present, removed first (after α-adrenergic blockade) to prevent a hypertensive crisis during thyroid surgery.

High-yield summary: MEN 1 (MEN1/menin, a tumor suppressor) = parathyroid, pituitary, and pancreatic tumors. MEN 2A (RET) = medullary thyroid carcinoma, pheochromocytoma, parathyroid hyperplasia. MEN 2B (RET) = medullary thyroid carcinoma, pheochromocytoma, mucosal neuromas, marfanoid habitus. Other familial pheochromocytoma syndromes: VHL, NF1, and succinate dehydrogenase (SDH) mutations.

Why the other options are wrong

  • A. Inactivating mutation of a tumor suppressor gene encoding menin — Inactivating MEN1 (menin) mutations cause MEN 1, characterized by parathyroid hyperplasia, pituitary adenomas, and pancreatic neuroendocrine tumors (e.g., gastrinoma); MEN 1 does not include medullary thyroid carcinoma or pheochromocytoma.
  • B. Inactivating mutation of the von Hippel-Lindau tumor suppressor gene — VHL mutations cause von Hippel-Lindau disease, with pheochromocytoma, clear cell renal cell carcinoma, cerebellar and retinal hemangioblastomas, and pancreatic cysts, but not medullary thyroid carcinoma or hyperparathyroidism.
  • D. Inactivating mutation of a gene encoding a Ras GTPase-activating protein — Loss of neurofibromin, a Ras GTPase-activating protein, causes neurofibromatosis type 1, which can include pheochromocytoma but is characterized by café-au-lait macules, neurofibromas, axillary freckling, and Lisch nodules, not medullary thyroid carcinoma.
  • E. Activating mutation of the gene encoding the Gsα protein subunit — Postzygotic activating GNAS mutations cause McCune-Albright syndrome (polyostotic fibrous dysplasia, café-au-lait macules with jagged borders, and autonomous endocrine hyperfunction such as precocious puberty), not medullary thyroid carcinoma or pheochromocytoma.

Key point

MEN 2A (medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia) is caused by autosomal dominant gain-of-function mutations in the RET receptor tyrosine kinase proto-oncogene.

Memory hook

MEN 2 = RET, an always-on receptor tyrosine kinase. 2A: MTC + pheo + parathyroid. 2B: MTC + pheo + mucosal neuromas, marfanoid.

Share: Telegram WhatsApp X LinkedIn

Practice like this every day

15 free bank questions a day, exam-length timed blocks, spaced repetition and 3D anatomy — in English and Russian.

Play free

More free questions in this system

Diabetic ketoacidosis with hypokalemia: potassium before insulinUSMLE Step 2 CK · EndocrineChronic aortic regurgitationUSMLE Step 1 · CardiovascularPharmacokinetics: volume of distribution and oral loading doseUSMLE Step 1 · PharmacologyAutosomal recessive recurrence risk (cystic fibrosis, unaffected sibling = 2/3 carrier)USMLE Step 1 · GeneticsAcyclovir-resistant HSV: thymidine kinase deficiencyUSMLE Step 1 · MicrobiologyCisplatin toxicity (ototoxicity, nephrotoxicity, hypomagnesemia): DNA cross-linkingUSMLE Step 1 · Hematology/Oncology

All free questions →